One year data from Kiadis Pharma’s ongo­ing Phase II tri­al with ATIR101™ will be pre­sent­ed at the American Society of Hematology 2016 Annual Meeting

Amsterdam, The Netherlands, November 3, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that data from the Company’s ongo­ing Phase II clin­i­cal tri­al (NCT01794299/EudraCT 2012-004461-41) with its lead prod­uct ATIR101™ has been select­ed by the American Society of Hematology (ASH) Program Committee for an oral pre­sen­ta­tion at the 58th Annual Meeting in San Diego, California on December 5, 2016.
The abstract will be pre­sent­ed by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and one of the prin­ci­pal inves­ti­ga­tors for the tri­al, and will pro­vide one year data from Kiadis Pharma’s inter­na­tion­al mul­ti-cen­ter study, in which a total of 23 leukemia patients, includ­ing patients with acute myeloid leukemia (AML), acute lym­phoblas­tic leukemia (ALL) and myelodys­plas­tic syn­drome (MDS), have been enrolled to be treat­ed with ATIR101™ as part of their trans­plant reg­i­men. In addi­tion, the abstract includes a com­par­i­son to a his­toric con­trol group.

Abstract title: Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL
Date: Monday, December 5, 2016 from 6:15 to 7:45 PM Eastern Daylight Time (EDT) (pre­sen­ta­tion time: 6:30 PM EDT)
Publication: 1226
Session: 711. Cell Collection and Processing: Immunotherapy, Immunomodulation and Immune Reconstitution
Location: San Diego Convention Center, Room 30

The full abstract is avail­able to view online at lat­er today at 9:00 AM EDT. In addi­tion, the abstract will be pub­lished online in the December 1, 2016 sup­ple­men­tal vol­ume of Blood.

Leave a Reply

Your email address will not be published. Required fields are marked *